A comparative analysis of lipid-complexed and liposomal amphotericin B preparations in haematological oncology

British Journal of Haematology

Volumn 103, Issue 1, 1998, Pages 198-204

  Clark, A D ^a,c   Mckendrick, S ^a   Tansey, P J ^a   Franklin, I M ^a   Chopra, R ^b  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Abelcet; AmBisome; Fungal infection; Lipid complex; Liposomes

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX;

ADULT; ANTIFUNGAL ACTIVITY; ARTICLE; DOSE RESPONSE; DRUG FORMULATION; ELECTROLYTE BALANCE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIPID ANALYSIS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; SCORING SYSTEM; TREATMENT OUTCOME;

ADULT; AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; ANTIFUNGAL AGENTS; CREATININE; DRUG COMBINATIONS; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNE TOLERANCE; LEUKOCYTE COUNT; MALE; MYCOSES; NEUTROPHILS; OPPORTUNISTIC INFECTIONS; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLGLYCEROLS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; WATER-ELECTROLYTE IMBALANCE;

EID: 0031710982     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1998.00934.x     Document Type: Article

References (25)

1. Adler Moore, J.P. (1994) AmBisome targeting to fungal infections. Bone Marrow Transplantation, 14, (Suppl. 5), S3-S7.
2. Beck Sague, C.M. & Jarvis, W.R. (1993) Secular trends in the epidemiology of nosocomial fungal infections in the USA, 1980-1990. Journal of Infections Diseases, 167, 1247-1251.
3. Bodey, G., Bueltmann, B., Duguid, W., Gibbs, G., Hanak, H., Hotchi, M., Mall, G., Martino, P., Meunier, F., Milliken, S., Naoe, S., Okudaira, M., Sceuola, D. & van't Wout, J. (1992) Fungal infections in cancer patients: an international autopsy survey. European Journal of Clinical Microbiology and Infectious Diseases, 11, 99-109.
4. De Marie, S. (1996) Liposomal and lipid based formulations of amphotericin B. Leukemia, 10, (Suppl. 2), S93-S96.
5. De Marie, S., Janknegt, R. & BakkerWoudenberg, I.A.J.M. (1994) Clinical use of liposomal and lipid complexed amphotericin B. Journal of Antimicrobial Chemotherapy, 33, 907-916.
6. Franklin, I.M., Mehta, J. & Root, T. (1997) The use of amphotericin B lipid complex. Journal of Antimicrobial Chemotherapy, 39, 288-290.
7. Hiemenz, J.W., Lister, J., Anaissie, E.J., White, M.H., Dinubile, M., Silber, J., Horwith, G. & Lee, L.W. (1995) Emergency use amphotericin B lipid complex versus amphotericin B in the treatment of patients with aspergillosis: historical control comparison with amphotericin B. Blood, 86, (Suppl. 1), 849a.
8. Hiemenz, J.W. & Walsh, T.J. (1996) Lipid formulations of amphotericin B: recent progress and future directions. Clinics in Infectious Diseases, 22, (Suppl. 2), S133-S144.
9. Hillery, A.M. (1997) Supramolecular lipidic drug delivery systems: from laboratory to clinic: a review of the recently introduced commercial liposomal and lipid based formulations of amphotericin B. Advances in Drug Delivery Systems, 24, 345-363.
10. Janknegt, R., de Marie, S., Bakker-Woudenberg, I.A. & Croumelin, D.J. (1992) Liposomal and lipid complexed formulations of amphotericin B. Clinical Pharmacokinetics, 4, 279-291.
11. Janoff, A.S., Perkin, W.R., Saletan, S.L. & Swenson, C.E. (1993) Amphotericin B lipid complex (ABLC): a molecular rationale for the attenuation of amphotericin B related toxicities. Journal of Liposomal Research, 3, 451-471.
12. Jantunen, E., Ruutu, P., Niskanen, L., Volin, L., Parkkali, T., Koukila-Kahkola, P. & Ruutu, T. (1997) Incidence and risk factors for invasive fungal infections in allogeneic bone marrow transplant recipients. Bone Marrow Transplantation, 19, 801-808.
13. Knaus, W.A., Draper, E.A., Wagner, D.P. & Zimmermann, J.E. (1985) APACHE II: a severity of disease classification system. Critical Care Medicine, 13, 818-829.
14. Knaus, W.A., Wagner, D.P., Draper, E.A., Zimmermann, J.E., Bergner, M., Bastos, P.G., Sirio, C.A., Murphy, D.J., Lotrius, T. & Dominio, A. (1991) The APACHE III prognostic system: risk prediction of hospital mortality for critically ill hospitalised patients. Chest. 100, 1619-1656.
15. Leenders, A.C.A.P. & de Marie, S. (1996) The use of lipid formulations of amphotericin B for systemic fungal infections. Leukemia, 10, 1570-1575.
16. Leenders, A.C.A.P., Daenan, S., Jansen, R.L.H., Hop, W.C.J., Lowenberg, E., Wijermans, P.W., Cornelissen, J., Herbrecht, R., van de Lelie, H., Hoogsteden, H.C., Verbrugh, H.A. & de Marie, S. (1998) Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. British Journal of Haematology, 103, 205-212.
17. Mehta, J. (1997) Do variations in molecular structure affect the clinical efficacy and safety of lipid based preparations of amphotericin B? Leukemia Research, 21, 183-188.
18. Mehta, J., Kelsey, S., Chu, P., Powles, R., Hazel, D., Riley, V., Evans, C., Newland, A., Treleaven, J. & Singhal, S. (1997) Amphotericin B lipid complex (ABLC) for the treatment of confirmed or presumed fungal infections in immunocompromised patients with hematological malignancies. Bone Marrow Transplantation, 20, 39-43.
19. Pizzo, P.A. (1995) Management of fever in patients with cancer and treatment-induced neutropenia. New England Journal of Medicine, 328, 1323-1332.
20. Prentice, H.G., Hann, I.M., Herbrecht, R., Aoun, M., Kvaloy, S., Catovsky, D., Pinkerton, C.R., Schey, S.A., Jacobs, E. Oakhill, A., Stevens, R.E. Darbyshire, P.J. & Gibson, B.E.S. (1997) A randomised comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. British Journal of Haematology, 98, 711-718.
21. Richardson, M.D. (1997) Lipid complexes of amphotericin B: the competitive picture. Journal of Medical Microbiology, 47, 185-187.
22. Richardson, M.D. & Kokki, M.H. (1998) Antifungal therapy in 'bone marrow failure'. British Journal of Haematology, 100, 619-628.
23. Ringden, O., Meunier, F.J., Ricci, P., Tura, S., Kuse, E., Viviani, M.A., Gorin, N.C., Klastersky, J., Fenaux, P., Prentice, H.G. & Ksionski, G. (1991) Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. Journal of Antimicrobial Chemotherapy, 28, (Suppl. B), 73-82.
24. Rogers, J. & Conway, A. (1998) Tolerability of low dose amphotericin B lipid complex (Abelcet) for the treatment of pyrexia of unknown origin (PUO) in neutropenic cancer patients. Bone Marrow Transplantation. 21, (Suppl. 1), S143.
25. Tollemar, J. & Ringden, O. (1995) Lipid formulations of amphotericin B: less toxicity but at what economic cost? Drug Safety, 13, 207-218.